Hypersensitivity of 5-HT2 receptors in OCD patients. An increased prolactin response after a challenge with meta-chlorophenylpiperazine and pre-treatment with ritanserin and placebo

Journal of Psychiatric Research

Volumn 42, Issue 11, 2008, Pages 894-901

  de Leeuw, Aart S ^a   Westenberg, Herman G M ^b  

^a Department of Anxiety Disorders ^*  (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Cortisol; MCPP; Obsessive compulsive disorder; Prolactin; Ritanserin; Serotonin receptors

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; HYDROCORTISONE; PLACEBO; PROLACTIN; RITANSERIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; 1-(3-CHLOROPHENYL)PIPERAZINE; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; SEROTONIN 2C RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BEHAVIOR; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN FUNCTION; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; FEMALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREMEDICATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PIPERAZINES; PREMEDICATION; PROLACTIN; RECEPTOR, SEROTONIN, 5-HT2C; RITANSERIN; SEROTONIN ANTAGONISTS; YOUNG ADULT;

EID: 47849094106     PISSN: 00223956     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2007.09.001     Document Type: Article

References (43)

1. Abi-Saab W., Seibyl J.P., D'Souza D.C., Karper L.P., Gueorgueva R., bi-Dargham A., et al. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms. Psychopharmacology (Berlin) 162 (2002) 55-62
2. Adams K.H., Hansen E.S., Pinborg L.H., Hasselbach S.G., Svarer C., Holm S., et al. Patients with obsessive-compulsive disorder have increased 5-HT2A receptor binding in the caudate nuclei. International Journal of Neuropsychopharmacology 8 3 (2005) 391-401
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th revised ed. Washington, DC: American Psychiatric Press; 1994.
4. Bagdy G., Szemeredi K., Kanyicska B., and Murphy D.L. Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats. Journal of Pharmacology and Experimental Therapeutics 250 (1989) 72-78
5. Bastani B., Nash J.F., and Meltzer H.Y. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder. Archives of General Psychiatry 47 (1990) 833-839
6. Baumann M.H., Mash D.C., and Staley J.K. The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain. Neuroreport 6 (1995) 2150-2152
7. Broocks A., Briggs N.C., Pigott T.A., Hill J.L., Canter S.K., Tolliver T.J., et al. Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment. Psychopharmacology (Berlin) 130 (1997) 91-103
8. Charney D.S., Woods S.W., Goodman W.K., and Heninger G.R. Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berlin) 92 (1987) 14-24
9. Charney D.S., Goodman W.K., Price L.H., Woods S.W., Rasmussen S.A., and Heninger G.R. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of tryptophan and m-chlorophenylpiperazine in patients and healthy subjects. Archives of General Psychiatry 45 (1988) 177-185
10. Eriksson E., Engberg G., Bing O., and Nissbrandt H. Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology 20 (1999) 287-296
11. Erzegovesi S., Martucci L., Henin M., and Bellodi L. Low versus standard dose mCPP challenge in obsessive-compulsive patients. Neuropsychopharmacology 24 (2001) 31-36
12. Feuchtl A., Bagli M., Stephan R., Frahnert C., Kolsch H., Kuhn K.U., et al. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. Pharmacopsychiatry 37 (2004) 180-188
13. Fuller R.W. Serotonergic stimulation of pituitary-adrenocortical function in rats. Neuroendocrinology 32 (1981) 118-127
14. Gatch M.B. Discriminative stimulus effects of m-chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety. Life Sciences 73 (2003) 1347-1367
15. Gijsman H.J., Van Gerven J.M., Tieleman M.C., Schoemaker R.C., Pieters M.S., Ferrari M.D., et al. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. Journal of Clinical Psychopharmacology 18 (1998) 289-295
16. Goodman W.K., Price L.H., Rasmussen S.A., Mazure C., Fleischmann R.L., Hill C.L., et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. Archives of General Psychiatry 46 (1989) 1006-1011
17. Goodman W.K., McDougle C.J., Price L.H., Barr L.C., Hills O.F., Caplik J.F., et al. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biological Psychiatry 38 (1995) 138-149
18. Hamik A., and Peroutka S.J. 1-(m-Chlorophenyl)piperazine (mCPP) interactions with neurotransmitter receptors in the human brain. Biological Psychiatry 25 (1989) 569-575
19. Hemrick-Luecke S.K., and Evans D.C. Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT(2A) receptor mediation of the HPA axis. Neuropharmacology 42 (2002) 162-169
20. Hewlett W.A., Vinogradov S., Martin K., Berman S., and Csernansky J.G. Fenfluramine stimulation of prolactin in obsessive-compulsive disorder. Psychiatry Research 42 (1992) 81-92
21. Hollander E., DeCaria C.M., Nitescu A., Gully R., Suckow R.F., Cooper T.B., et al. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Archives of General Psychiatry 49 (1992) 21-28
22. Hollander E., Cohen L.J., DeCaria C., Saoud J.B., Stein D.J., Cooper T.B., et al. Timing of neuroendocrine responses and effect of m-CPP and fenfluramine plasma levels in OCD. Biological Psychiatry 34 (1993) 407-413
23. Ho Pian K.L., Westenberg H.G., den Boer J.A., de Bruin W.I., and van Rijk P.P. Effects of meta-chlorophenylpiperazine on cerebral blood flow in obsessive-compulsive disorder and controls. Biological Psychiatry 44 (1998) 367-370
24. Hoyer D. Functional correlates of serotonin 5-HT1 recognition sites. Journal of Receptor Research 8 (1988) 59-81
25. Kahn R.S., and Wetzler S. m-Chlorophenylpiperazine as a probe of serotonin function. Biological Psychiatry 30 (1991) 1139-1166
26. Kahn R.S., Wetzler S., van Praag H.M., Asnis G.M., and Strauman T. Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Research 25 (1988) 101-104
27. Kahn R.S., Kalus O., Wetzler S., Cahn W., Asnis G.M., and van Praag H.M. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. Psychiatry Research 33 (1990) 189-198
28. Khanna S., John J.P., and Reddy L.P. Neuroendocrine and behavioral responses to mCPP in obsessive-compulsive disorder. Psychoneuroendocrinology 26 (2001) 209-223
29. Lucey J.V., O'Keane V., Butcher G., Clare A.W., and Dinan T.G. Cortisol and prolactin responses to d-fenfluramine in non-depressed patients with obsessive-compulsive disorder: a comparison with depressed and healthy controls. British Journal of Psychiatry 161 (1992) 517-521
30. McBride P.A., DeMeo M.D., Sweeney J.A., Halper J., Mann J.J., and Shear M.K. Neuroendocrine and behavioral responses to challenge with the indirect serotonin agonist dl-fenfluramine in adults with obsessive-compulsive disorder. Biological Psychiatry 31 (1992) 19-34
31. McNair D.M., Lorr M., and Droppelman L.F. Manual for the profile of mood states (1971), Educational and Industrial Testing Service, San Diego, CA
32. Mueller E.A., Murphy D.L., and Sunderland T. Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans. Journal of Clinical Endocrinology and Metabolism 61 (1985) 1179-1184
33. Mueller E.A., Murphy D.L., and Sunderland T. Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans. Psychopharmacology (Berlin) 89 (1986) 388-391
34. Murphy D.L., Mueller E.A., Hill J.L., Tolliver T.J., and Jacobsen F.M. Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology (Berlin) 98 (1989) 275-282
35. Pigott T.A., Hill J.L., Grady T.A., L'Heureux F., Bernstein S., Rubenstein C.S., et al. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biological Psychiatry 33 (1993) 3-14
36. Porter R.H., Benwell K.R., Lamb H., Malcolm C.S., Allen N.H., Revell D.F., et al. Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells. British Journal of Pharmacology 128 (1999) 13-20
37. Rothman R.B., and Baumann M.H. Serotonin releasing agents. Neurochemical, therapeutic and adverse effects. Pharmacology, Biochemistry and Behavior 71 (2002) 825-836
38. Seibyl J.P., Krystal J.H., Price L.H., Woods S.W., D'Amico C., Heninger G.R., et al. Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Research 38 (1991) 227-236
39. Silverstone P.H., and Cowen P.J. The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (mCPP)-induced changes in human volunteers. Biological Psychiatry 36 (1994) 309-316
40. Thijssen J.H., van den Berg J.H., Adlercreutz H., Gijzen A.H., de Jong F.H., Meijer J.C., et al. The determination of cortisol in human plasma: evaluation and comparison of seven assays. Clinica Chimica Acta 100 (1980) 39-46
41. Yamauchi M., Miyara T., Matsushima T., and Imanishi T. Desensitization of 5-HT(2A) receptor function by chronic administration of selective serotonin reuptake inhibitors. Brain Research 1067 (2006) 164-169
42. Zhang Y., Damjanoska K.J., Carrasco G.A., Dudas B., D'souza D.N., Tetzlaff J., et al. Evidence that 5-HT2A receptors in the hypothalamic paraventricular nucleus mediate neuroendocrine responses to (-)DOI. Journal of Neuroscience 22 (2002) 9635-9642
43. Zohar J., Mueller E.A., Insel T.R., Zohar-Kadouch R.C., and Murphy D.L. Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Archives of General Psychiatry 44 (1987) 946-951